Malaria Vaccine Development and Erythrocyte Invasion Mechanisms

Malaria remains a global health challenge, driven by the blood-stage replication of Plasmodium falciparum within human erythrocytes. Vaccine development has long targeted both pre-erythrocytic stages, to prevent liver infection, and blood stages, to block symptomatic disease. Central to blood-stage infection is the merozoite, which deploys a succession of receptor–ligand interactions to attach to, deform, and penetrate red blood cells. Key invasion proteins—most notably reticulocyte-binding protein homolog 5 (RH5), cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR)—form a heterotrimeric RCR complex essential for tight junction formation and internalisation. Antibodies that neutralise these proteins can synergise to inhibit erythrocyte entry. Modern vaccine strategies leverage structural biology and immunogen design to present conserved growth-inhibitory epitopes, employ virus-like particles or adjuvants to enhance potency, and integrate multi-antigen formulations to overcome natural antigenic diversity. Clinical trials in endemic settings have begun to demonstrate safety, robust immune responses and functional growth inhibition, signalling promise for next-generation blood-stage vaccines.

Research from Nature Portfolio

Recent structural analyses have resolved the architecture of the RH5–CyRPA–RIPR core (RCR) complex at near-atomic resolution, revealing how conserved interfaces present sequential binding surfaces for erythrocyte receptors and vaccine-elicited antibodies. These insights demonstrated that RH5 remains rigid during receptor engagement and that CyRPA-binding antibodies neutralise invasion via steric hindrance. Complementary preclinical work examined combined immunisation with the three RCR components. Although polyclonal responses to RIPR proved suboptimal alone, fusion constructs linking the growth-inhibitory C-terminal domains of RIPR to CyRPA and co-formulated with RH5 induced additive and sometimes synergistic antibody activity in vitro. Together, these studies inform rational vaccine design by pinpointing optimal antigen combinations and epitope presentations for enhanced blood-stage protection.

Malaria Vaccine Development and Erythrocyte Invasion Mechanisms publication trend

The graph below shows the total number of articles in malaria vaccine development and erythrocyte invasion mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

merozoite: The invasive blood-stage form of Plasmodium falciparum that enters erythrocytes.

RCR complex: The heterotrimeric assembly of RH5, CyRPA and RIPR essential for erythrocyte invasion.

RH5: Reticulocyte-binding protein homolog 5, a conserved parasite ligand critical for tight junction formation.

CyRPA: Cysteine-rich protective antigen, a RCR subunit that binds to erythrocyte surfaces and is targeted by neutralising antibodies.

RIPR: RH5-interacting protein, an RCR subunit with EGF-like domains presenting inhibitory epitopes.

Matrix-M adjuvant: A saponin-based immunostimulatory formulation used to enhance antibody responses to vaccine antigens.

growth inhibition activity (GIA): An in vitro assay measuring the ability of antibodies to prevent parasite replication in erythrocytes.

References

1. The PfRCR complex bridges malaria parasite and erythrocyte during invasion. Nature (2023).
2. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype. Cell (2024).
3. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial. The Lancet Infectious Diseases (2024).
4. Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex. Nature Communications (2024).
5. Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5. EMBO Molecular Medicine (2024).